COLAL-PRED Alizyme

Stephen B. Hanauer, Miles Sparrow

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

COLAL-PRED (prednisolone sodium metasulfobenzoate), which is targeted to the colon by COLAL colonic drug delivery technology, is being developed by Alizyme for the potential treatment of inflammatory bowel disease. Alizyme expect to initiate a phase III trial in 2005.

Original languageEnglish
Pages (from-to)1192-1197
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Volume5
Issue number11
Publication statusPublished - Nov 2004
Externally publishedYes

Cite this